Clinical Trials Summary

Genetics in Parkinson's Disease PaGeR The PaGeR Study: Using Multiplex Families to Map Genes that Modify Susceptibility and Age at Onset in Parkinson’s Disease Fredy J Revilla, MD (PI)
Parkinson's Disease –Newly Diagnosed PPMI 11-12-20-09 Parkinson's Progression Markers Initiative (PPMI) Alberto Espay, MD (PI)
Parkinson's with Dyskinesia ADS-AMT-PD301 Efficacy and Safety of ADS-5102 (Amantadine HCL) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (Ease LID Study) Alberto Espay, MD (PI)
Parkinson's with Dyskinesia ADS-AMT-PD302 Open-Label Safety Study of ADS-5102 (Amantadine HCL) Extended Release Capsules for the Treatment of Levodopa Induced Dyskenesia Alberto Espay, MD (PI)
Parkinson's Disease Timed Motor Battery Testing Alberto Espay, MD (PI)
Huntington's Disease with Chorea SD-809-C-16 An Open-Label, Long-Term Safety Study of SD-809 ER in Subjects with Chorea Associated with Huntington Disease Fredy J. Revilla, MD (PI)
Cervical Dystonia Cervical Dystonia Alberto Espay, MD (PI)
Huntington's Disease Enroll-HD: A Prospective Registry Study in a Global Huntingtons's Disease Cohort Fredy J. Revilla, MD (PI)
Huntington's Disease with Chorea SD-809-C-15 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated with Huntington Disease Fredy J. Revilla, MD (PI)
Parkinson's with Dyskinesia KO6002-014 A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson’s Disease Andrew Duker, MD (PI)
Parkinson's Disease with Motor Fluctuations M12-920 An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Crbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease Alberto Espay, MD (PI)
Sialorrhea (Problematic Drooling) A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment with MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects Alberto Espay, MD (PI)
Dystonia Natural History and Bio-specimen Repository for Dystonia Alberto Espay, MD (PI)
Parkinson's Disease Dementia PANUC PANUC Clinical Core Fredy J. Revilla, MD (PI)
Idiopathic PD ParkinStep: Automated PD Gait and Balance Assessment for DBS Programming Alberto Espay, MD (PI)
Parkinson's disease Naturalistic Study on Treatment Response in PD Alberto Espay, MD (PI)
Parkinson's Disease – Newly Diagnosed P2B001/001 A Phase 2B, Twelve-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety, Tolerability, and Efficacy of Two Doses of Once Daily P2B001 in Subjects with Early Parkinson's Disease (PD) Andrew Duker, MD (PI)
Risk Factors for the Development of Parkinson's Disease Pre-PPMI The Parkinson's Progression Markers Initiative Alberto Espay, MD (PI)
Psychogenic Tremor K23 Psychogenic Tremor: Functional Magnetic Resonance Study of Emotional Processing Alberto Espay, MD (PI)
Parkinson's Disease with Motor Fluctuations Open-Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Who Have Exhibited a Persistent and Positive Effect To Treatment in Previous Studies Alberto Espay, MD (PI)
Parkinson's Disease – Newly Diagnosed A Phase 3 Double-Blind Placebo-Controlled Parallel Group Study of Isradipine as a Disease-Modifying Agent in Subjects with Early Parkinson Disease Alok Sahay, MD (PI)